Survival Improving in Metastatic Bladder Cancer
The median survival for patients with metastatic bladder cancer is increasing, possibly due to increasing use of immunotherapy.
The median survival for patients with metastatic bladder cancer is increasing, possibly due to increasing use of immunotherapy.
The rising cost of care is having a negative impact on patients with bladder cancer, but a value-based approach to care might provide some relief.
Patients undergoing radical cystectomy for bladder cancer have an increased risk of thromboembolic events that may persist for months after surgery.
Total hospital costs related to radical cystectomy are higher in the West than in all other regions of the United States, a study suggests.
Aortic calcification may lead to arterial degradation that increases the risk for acute kidney injury, according to investigators.
Gemcitabine plus docetaxel “may serve as a reasonable alternative first-line therapy for patients with high-risk NMIBC during the ongoing BCG shortage,” according to researchers.
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
A protocol for eliminating routine opioid prescription after major urologic cancer surgery was both safe and successful, according to researchers.
Pembrolizumab demonstrated antitumor activity in patients with high-risk, papillary NMIBC who did not undergo radical cystectomy and did not respond to BCG.
Sacituzumab govitecan has demonstrated activity in patients with platinum-ineligible metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy.